The cobas e 601 module is a fully automated analyzer that uses a patented electrochemiluminescence (ECL) technology for immunoassay analysis.
It is designed for both quantitative and qualitative in vitro assay determinations for a broad range of applications (including anemia; bone, cardiac and tumor markers; critical care; fertility/hormones; maternal care; and infectious diseases).
The cobas e 411 analyzer is a fully automated analyzer that uses a patented ElectroChemiLuminescence (ECL) technology for immunoassay analysis.
It is designed for both quantitative and qualitative in vitro assay determinations for a broad range of applications (including anemia; bone, cardiac and tumor markers; critical care; fertility/hormones; maternal care; and infectious diseases).
Chemiluminescence Immunoassay (CLIA) System
CLIA uses two important technologies, one is labeling technology which determines reaction mode; and the other is
separation technology which determines the sensitivity, accuracy and precision of the reagents.
Sample Loading
Up to 144 primary tubes, Continuous loading, STAT available, Barcode reader recognition or analyzer auto numbered, LIS connection, auto read sample info, Refrigerated sample area with independent power supply
Reagent Loading
25 reagents on board, Continuous loading, RFID reading all info of reagents, Refrigerated reagent area.
Reagent Features
Integrated kit, ready-to-use, no pretreatment required, Integrated kit including calibrators, Using superparamagnetic micrbeads, RFID tag storing all info of reagent, RFID tag with built-in master curve, 2-point calibration to adjust master curve, Calibration stability: Max 4 weeks.
The highly reliable IMMULITE® 2000 XPi system is easy to use and has one of the largest automated immunoassay menus available. Medium- to high-volume laboratories can incorporate specialty and allergy testing into routine workloads to improve productivity and efficiency.
The BN ProSpec® is a dedicated, compact system that offers a consolidated menu of specialty and routine reagents for reliable plasma protein testing including cardiac risk assessment, kidney diseases, nutritional assessment and iron and anemia assessment as well as innovative markers such as monoclonal kappa and lambda free light chains, Cystatin C and Carbohydrate-Deficient Transferrin (CDT).
Easy-to-use single test multiparametric system for immunometric assay.
SAFE AND USER FRIENDLY
minimal manual operation required:
1.Dispense the serum into the device
2.Place the device in the instrument
3.Press RUN: the instrument is programmed by the device’s bar-code label.
CONVENIENT SYSTEM
The single test device contains all the reagents necessary to perform the assay: no hidden costs or waste of reagents. Master curve procedure with 1 point calibrator included in the kit. Packaging: 36 or 12 devices according to the type of test
Specimen: Serum
Specimen Stability: 3 days 2-8 C, Long storage require -20 C
Principle and method: ELISA
Specimen Volume: 1 mL
Turnaround Time (TAT): 1 Month
Department: Immunology & Serology
Specimen: Serum.
Specimen Stability: 4 days at 2/8°C, or frozen for longer periods at –20°C
Principle and method: ELISA
Specimen Volume: 1 mL
Device: Diesse Chorus Trio
Turnaround Time (TAT): Daily
Department: Immunology & Serology
Specimen: Serum.
Specimen Stability: 4 days at 2/8°C, or frozen for longer periods at –20°C
Principle and method: ELISA
Specimen Volume: 1 mL
Device: Diesse Chorus Trio
Turnaround Time (TAT): Daily
Department: Immunology & Serology
This Section is Under Construction
Specimen: Serum.
Specimen Stability: 4 days at 2/8°C, or frozen for longer periods at –20°C
Principle and method: ELISA
Specimen Volume: 1 mL
Device: Diesse Chorus Trio
Turnaround Time (TAT): 3 Days
Department: Immunology & Serology
Specimen: Serum.
Specimen Stability: 4 days at 2/8°C, or frozen for longer periods at –20°C
Principle and method: ELISA
Specimen Volume: 1 mL
Device: Diesse Chorus Trio
Turnaround Time (TAT): 2 Days
Department: Immunology & Serology
Specimen: Serum.
Specimen Stability: 3 days at 2‑8 °C, 1 month at ‑20 °C
Principle and method: ECLIA
Specimen Volume: 1 mL
Device: Roche E170
Turnaround Time (TAT): Daily
Department: Immunology & Serology
Limitations: The anti‑CCP test results can be false negative in patients with hypergammaglobulinemia. Results from patients suffering from this disorder should not be used for diagnostic purposes.
Specimen: Serum.
Specimen Stability: 4 days at 2/8°C, or frozen for longer periods at –20°C
Principle and method: ELISA
Specimen Volume: 1 mL
Device: Diesse Chorus Trio
Turnaround Time (TAT): 2 Days
Department: Immunology & Serology
Specimen: Serum.
Specimen Stability: 4 days at 2/8°C, or frozen for longer periods at –20°C
Principle and method: ELISA
Specimen Volume: 1 mL
Device: Diesse Chorus Trio
Turnaround Time (TAT): 2 Days
Department: Immunology & Serology
Specimen: Serum.
Specimen Stability: Up to 48 h at 2-8°C, or frozen at -20°C for longer periods
Principle and method: immunofluorescence (IF)
Specimen Volume: 1 mL
Turnaround Time (TAT): Weekly
Department: Immunology & Serology
Specimen: Serum.
Specimen Stability: Up to 48 h at 2-8°C, or frozen at -20°C for longer periods
Principle and method: immunofluorescence (IF)
Specimen Volume: 1 mL
Turnaround Time (TAT): Weekly
Department: Immunology & Serology
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction
This Section is Under Construction